High Dyspnea Score, a Trigger for Specialist Palliative Care Utilization—Results from a Cohort Study on the Predictors of High Opioid and Benzodiazepine Use in COVID-19 Patients
Publication: Journal of Palliative Medicine
Abstract
Background: Patients with severe coronavirus disease 2019 (COVID-19) often rapidly deteriorate with severe dyspnea and should receive early specialist palliative care (SPC) as intensive symptom management may be required at the end of life. Currently, there is a paucity of data identifying triggers for early SPC involvement.
Objective: To identify risk factors among nonventilated patients with severe COVID-19 who required high opioid and/or benzodiazepines (BZD) use for the control of dyspnea.
Methods: This is a retrospective cohort study of nonventilated patients with COVID-19 admitted to the National Centre for Infectious Diseases in Singapore and seen by SPC between January 2021 and July 2022. We collected baseline demographics, comorbidities, 4C mortality score (International Severe Acute Respiratory Infection Consortium—Comprehensive Clinical Characterization Collaboration [ISARIC-4C]), and COVID-19 vaccination status. Clinical and laboratory results, dyspnea by numerical rating scale, and palliative-related treatments were recorded at the first SPC review, when symptoms peaked, and the last SPC review. Patients with morphine equivalent daily dose (MEDD) of ≥45mg and/or BZD use for dyspnea control were grouped as high users, while patients with MEDD <45mg and no BZD use were low users.
Results: Among 234 patients, 119 (50.9%) were high users. Multivariate analysis showed that subjects with higher dyspnea (odds ratio [OR] 1.74, 95% confidence interval [CI] 1.45–2.08) and lower ISARIC-4C scores (OR 0.77, 95% CI 0.67–0.88) at first SPC review were predictive of high users. High users also required higher supplemental oxygen and had higher inpatient mortality rates.
Conclusions: High dyspnea score is predictive of high opioid and/or BZD use for symptom control in nonventilated patients with severe COVID-19. Such patients with high mortality rates should be seen early by SPC.
Get full access to this article
View all available purchase options and get full access to this article.
References
1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020;395(10229):1054–1062.
2. Alderman B, Webber K, Davies A. An audit of end-of-life symptom control in patients with corona virus disease 2019 (COVID-19) dying in a hospital in the United Kingdom. Palliat Med 2020;34(9):1249–1255.
3. Wong AK, Philip J, Wawryk O, et al. A multi-centre COVID-19 study examining symptoms and medication use in the final week of life. J Pain Symptom Manage 2022;64(3):e139-47–e147.
4. Keeley P, Buchanan D, Carolan C, et al. Symptom burden and clinical profile of COVID-19 deaths: A rapid systematic review and evidence summary. BMJ Support Palliat Care 2020;10(4):381–384.
5. Ho EP, Neo HY. COVID 19: Prioritise autonomy, beneficence and conversations before score-based triage. Age Ageing 2021;50(1):11–15.
6. Lovell N, Maddocks M, Etkind SN, et al. Characteristics, symptom management, and outcomes of 101 patients with COVID-19 referred for hospital palliative care. J Pain Symptom Manage 2020;60(1):e77-81–e81.
7. Higginson IJ, Hocaoglu MB, Fraser LK, et al. CovPall study team. Symptom control and survival for people severely ill with COVID: A multicentre cohort study (CovPall-Symptom). J Pain Symptom Manage 2022;64(4):377–390.
8. Strang P, Bergström J, Lundström S. Symptom relief is possible in elderly dying COVID-19 patients: A national register study. J Palliat Med 2021;24(4):514–519.
9. Heath L, Carey M, Lowney AC, et al. Pharmacological strategies used to manage symptoms of patients dying of COVID-19: A rapid systematic review. Palliat Med 2021;35(6):1099–1107.
10. Knight SR, Ho A, Pius R, et al. ISARIC4C investigators. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: Development and validation of the 4C mortality score. BMJ 2020;370:m3339.
11. Tan TH, Toh MP, Vasoo S, et al. Coronavirus disease 2019 (COVID-19): The Singapore experience. A review of the first eight months. Ann Acad Med Singap 2020;49(10):764–778.
12. Katz S. Assessing self-maintenance: Activities of daily living, mobility, and instrumental activities of daily living. J Am Geriatr Soc 1983;31(12):721–727.
13. Anderson F, Downing GM, Hill J, et al. Palliative Performance Scale (PPS): A new tool. J Palliat Care 1996;12(1):5–11.
14. Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47(11):1245–1251.
15. Hui D, Bruera E. The Edmonton symptom assessment system 25 years later: Past, present, and future developments. J Pain Symptom Manage 2017;53(3):630–643.
16. Heinze G, Wallisch C, Dunkler D. Variable selection–a review and recommendations for the practicing statistician. Biom J 2018;60(3):431–449.
17. Team RD. R: A language and environment for statistical computing. (No Title). 2010.
18. Von Elm E, Altman DG, Egger M, et al. STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Lancet 2007;370(9596):1453–1457.
19. Meek PM. Dyspnoea mechanisms, assessment, and management: A consensus statement. Am J Respir Crit Care Med 1999;159:321–340.
20. Menga LS, Grieco DL, Rosà T, et al. Dyspnoea and clinical outcome in critically ill patients receiving noninvasive support for COVID-19 respiratory failure: Post hoc analysis of a randomised clinical trial. ERJ Open Res 2021;7(4).
21. Zaboli A, Ausserhofer D, Pfeifer N, et al. The ROX index can be a useful tool for the triage evaluation of COVID‐19 patients with dyspnoea. J Adv Nurs 2021;77(8):3361–3369.
22. Puah SH, Young BE, Chia PY, et al. Singapore 2019 novel coronavirus outbreak research team. Clinical features and predictors of severity in COVID-19 patients with critical illness in Singapore. Sci Rep 2021;11(1):7477.
23. Durie ML, Neto AS, Burrell AJ, et al. SPRINT-SARI Australia Investigators. ISARIC-4C mortality score overestimates risk of death due to COVID-19 in Australian ICU patients: A validation cohort study. Crit Care Resusc 2021;23(4):403–413.
24. Crocker-Buque T, Myles J, Brentnall A, et al. Using ISARIC 4C mortality score to predict dynamic changes in mortality risk in COVID-19 patients during hospital admission. PLoS One 2022;17(10):e0274158.
25. Sim J, Goh WY, Wiryasaputra L, et al. Use of phenobarbitone for palliative sedation in dyspneic crises due to COVID-19 pneumonia–A case series. J Pain Palliat Care Pharmacother 2022;36(4):242–248.
26. Fried TR, Zenoni M, Iannone L, et al. Assessment of surrogates’ knowledge of patients’ treatment goals and confidence in their ability to make surrogate treatment decisions. JAMA Intern Med 2019;179(2):267–268.
Information & Authors
Information
Published In
Journal of Palliative Medicine
Copyright
Copyright 2024, Mary Ann Liebert, Inc., publishers.
History
Published online: 26 November 2024
Accepted: 26 October 2024
Authors
Author Disclosure Statement
The authors declare that there is no conflict of interest.
Funding Information
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.